Donepezil for mild cognitive impairment in Parkinson’s disease

We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Baik, Kyoungwon, Kim, Seon Myeong, Jung, Jin Ho, Lee, Yang Hyun, Chung, Seok Jong, Yoo, Han Soo, Ye, Byoung Seok, Lee, Phil Hyu, Sohn, Young H., Kang, Seung Wan, Kang, Suk Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910590/
https://www.ncbi.nlm.nih.gov/pubmed/33637811
http://dx.doi.org/10.1038/s41598-021-84243-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910590/
https://www.ncbi.nlm.nih.gov/pubmed/33637811
http://dx.doi.org/10.1038/s41598-021-84243-4

Ejemplares similares